PMID- 25370794
OWN - NLM
STAT- MEDLINE
DCOM- 20151110
LR  - 20211021
IS  - 1573-6903 (Electronic)
IS  - 0364-3190 (Linking)
VI  - 40
IP  - 1
DP  - 2015 Jan
TI  - Prolyl carboxypeptidase activity decline correlates with severity and short-term 
      outcome in acute ischemic stroke.
PG  - 81-8
LID - 10.1007/s11064-014-1468-y [doi]
AB  - Prolyl carboxypeptidase (PRCP) is an enzyme associated with cerebrovascular risk 
      factors such as hypertension, diabetes mellitus, obesity and hyperlipidemia. We 
      aim to evaluate the relation between serum PRCP activity and severity, evolution 
      and outcome of acute ischemic stroke. We used a specific RP-HPLC activity assay 
      to measure PRCP activity in serum of 50 stroke patients at admission, and at 24 
      h, 72 h and 7 days after stroke onset to assess correlations with stroke severity 
      based on the National Institutes of Health Stroke scale score (NIHSS), infarct 
      volume on brain MRI scan, stroke outcome based on the modified Rankin scale (mRS) 
      and mortality at 3 months after stroke. The average PRCP activity in serum 
      decreased significantly the first 24 h after stroke onset and returned to 
      baseline values at day 7. High NIHSS scores and infarct volumes at admission were 
      related with a more pronounced decrease of PRCP in the first 24 h after stroke 
      (DeltaPRCP24, r = 0.31, P < 0.05; r = 0.30, P < 0.05). In addition, patients who 
      displayed a more pronounced decrease in PRCP levels during the first 24 h after 
      stroke were more likely to be institutionalized upon discharge (n = 21) (DeltaPRCP24 
      +/- SD, 0.05 +/- 0.10 U/L vs. 0.17 +/- 0.14 U/L, P = 0.001). The decrease in PRCP 
      levels in the first 24 h after stroke onset is associated with stroke severity 
      and an unfavourable short-term stroke outcome.
FAU - Kehoe, Kaat
AU  - Kehoe K
AD  - Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, 
      University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
FAU - Brouns, Raf
AU  - Brouns R
FAU - Verkerk, Robert
AU  - Verkerk R
FAU - Engelborghs, Sebastiaan
AU  - Engelborghs S
FAU - De Deyn, Peter Paul
AU  - De Deyn PP
FAU - Hendriks, Dirk
AU  - Hendriks D
FAU - De Meester, Ingrid
AU  - De Meester I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141105
PL  - United States
TA  - Neurochem Res
JT  - Neurochemical research
JID - 7613461
RN  - EC 3.4.- (Carboxypeptidases)
RN  - EC 3.4.16.2 (lysosomal Pro-X carboxypeptidase)
SB  - IM
MH  - Aged
MH  - Brain Ischemia/*enzymology/pathology
MH  - Carboxypeptidases/blood/*metabolism
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Stroke/*enzymology/pathology
MH  - Treatment Outcome
EDAT- 2014/11/06 06:00
MHDA- 2015/11/11 06:00
CRDT- 2014/11/06 06:00
PHST- 2014/08/04 00:00 [received]
PHST- 2014/10/27 00:00 [accepted]
PHST- 2014/10/14 00:00 [revised]
PHST- 2014/11/06 06:00 [entrez]
PHST- 2014/11/06 06:00 [pubmed]
PHST- 2015/11/11 06:00 [medline]
AID - 10.1007/s11064-014-1468-y [doi]
PST - ppublish
SO  - Neurochem Res. 2015 Jan;40(1):81-8. doi: 10.1007/s11064-014-1468-y. Epub 2014 Nov 
      5.